Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Aytu BioPharma (NASDAQ:AYTU) has announced it will release its fiscal 2025 second quarter operational and financial results on February 12, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. Eastern time, featuring a results review and Q&A session.
Investors can join the conference call by dialing (888) 506-0062 (US) or +1 (973) 528-0011 (international) using access code 583044. The webcast will be available live and archived at the company’s investor relations website. A replay will be accessible until February 26, 2025.
Aytu BioPharma (NASDAQ:AYTU) ha annunciato che rilascerà i suoi risultati operativi e finanziari per il secondo trimestre fiscale 2025 il 12 febbraio 2025, dopo la chiusura del mercato. L’azienda ospiterà una conferenza telefonica e una trasmissione in webcast lo stesso giorno alle 16:30 ora orientale, con una revisione dei risultati e una sessione di domande e risposte.
Gli investitori possono unirsi alla conferenza telefonica componendo il numero (888) 506-0062 (USA) o +1 (973) 528-0011 (internazionale) utilizzando il codice di accesso 583044. Il webcast sarà disponibile in diretta e archiviato sul sito web delle relazioni con gli investitori dell’azienda. Una registrazione sarà accessibile fino al 26 febbraio 2025.
Aytu BioPharma (NASDAQ:AYTU) ha anunciado que publicará sus resultados operativos y financieros del segundo trimestre fiscal 2025 el 12 de febrero de 2025, después del cierre del mercado. La compañía llevará a cabo una conferencia telefónica y una transmisión en webcast el mismo día a las 4:30 p.m. hora del Este, con una revisión de resultados y una sesión de preguntas y respuestas.
Los inversores pueden unirse a la conferencia telefónica marcando el (888) 506-0062 (EE.UU.) o +1 (973) 528-0011 (internacional) utilizando el código de acceso 583044. La transmisión en webcast estará disponible en vivo y archivada en el sitio web de relaciones con inversionistas de la empresa. Una repetición estará accesible hasta el 26 de febrero de 2025.
Aytu BioPharma (NASDAQ:AYTU)는 2025 회계연도 2분기 운영 및 재무 결과를 2025년 2월 12일에 시장 마감 후 발표할 것이라고 발표했습니다. 회사는 같은 날 동부 표준시 오후 4시 30분에 결과 검토와 질의응답 세션을 포함한 회의 전화 및 웹캐스트를 진행할 것입니다.
투자자들은 (888) 506-0062 (미국) 또는 +1 (973) 528-0011 (국제)로 전화하여 접근 코드 583044를 이용해 회의에 참여할 수 있습니다. 웹캐스트는 회사의 IR 웹사이트에서 실시간으로 진행되며 아카이브로 남겨질 것입니다. 재생은 2025년 2월 26일까지 가능할 것입니다.
Aytu BioPharma (NASDAQ:AYTU) a annoncé qu’elle publiera ses résultats opérationnels et financiers pour le deuxième trimestre fiscal 2025 le 12 février 2025, après la clôture du marché. L’entreprise organisera une conférence téléphonique et un webcast le même jour à 16h30, heure de l’Est, comprenant un examen des résultats et une session de questions-réponses.
Les investisseurs peuvent rejoindre la conférence téléphonique en composant le (888) 506-0062 (États-Unis) ou le +1 (973) 528-0011 (international) en utilisant le code d’accès 583044. Le webcast sera disponible en direct et archivé sur le site web des relations investisseurs de l’entreprise. Un replay sera accessible jusqu’au 26 février 2025.
Aytu BioPharma (NASDAQ:AYTU) hat angekündigt, dass die operativen und finanziellen Ergebnisse für das zweite Quartal des Geschäftsjahres 2025 am 12. Februar 2025 nach Börsenschluss veröffentlicht werden. Das Unternehmen wird am selben Tag um 16:30 Uhr Eastern Time eine Telefonkonferenz und einen Webcast abhalten, in dem eine Ergebnisübersicht und eine Frage-und-Antwort-Runde stattfinden werden.
Investoren können an der Telefonkonferenz teilnehmen, indem sie (888) 506-0062 (USA) oder +1 (973) 528-0011 (international) wählen und den Zugangscode 583044 verwenden. Der Webcast wird live und archiviert auf der Investor-Relations-Website des Unternehmens verfügbar sein. Eine Wiederholung ist bis zum 26. Februar 2025 zugänglich.
DENVER, CO / ACCESS Newswire / February 5, 2025 / Aytu BioPharma, Inc. (the “Company” or “Aytu”) (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its operational and financial results for its second quarter of fiscal 2025, after the market close on Wednesday, February 12, 2025. The Company has scheduled a conference call and webcast that same day, Wednesday, February 12, 2025, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.
Conference Call Details
Date and Time: Wednesday, February 12, 2025, at 4:30 p.m. Eastern time
Call-in Information: Interested parties can access the conference call by dialing (888) 506-0062 for United States callers or +1 (973) 528-0011 for international callers and using the participant access code 583044.
Webcast Information: The webcast will be accessible live and archived at https://www.webcaster4.com/Webcast/Page/2142/51953, and accessible on the Investors section of the Company’s website at https://investors.aytubio.com/ under Events & Presentations.
Replay: A teleconference replay of the call will be available until February 26, 2025 at (877) 481-4010 for U.S. callers or +1 (919) 882-2331 for international callers and using replay access code 51953.
About Aytu BioPharma, Inc.
Aytu is a pharmaceutical company focused on commercializing novel therapeutics. The Company’s prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. To learn more, please visit aytubio.com.
Contacts for Investors
Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
rselhorn@aytubio.com
Robert Blum or Roger Weiss
Lytham Partners
aytu@lythampartners.com
SOURCE: Aytu BioPharma, Inc
View the original press release on ACCESS Newswire
FAQ
When will Aytu BioPharma (AYTU) report its Q2 2025 earnings?
Aytu BioPharma will report its fiscal 2025 second quarter results on February 12, 2025, after market close.
How can investors access AYTU’s Q2 2025 earnings call?
Investors can access the call by dialing (888) 506-0062 (US) or +1 (973) 528-0011 (international) with access code 583044, or via webcast at the company’s investor relations website.
What time is AYTU’s Q2 2025 earnings conference call?
The earnings conference call is scheduled for Wednesday, February 12, 2025, at 4:30 p.m. Eastern time.
How long will AYTU’s Q2 2025 earnings call replay be available?
The earnings call replay will be available until February 26, 2025.
